VEVeru Inc. VERU · NASDAQ
$2.13 -2.74% (-$0.06)
- Market cap
- $34.2M
- Enterprise value
- $13.0M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -60.6%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- -1.20
- Free float
- 87.2%
About the company
Veru Inc. (VERU) is an American pharmaceutical company focused on research, development, and commercialization of therapeutic products in the fields of urology and oncology. The company specializes in the treatment of oncological diseases, including prostate, breast, and other malignancies. Veru is also involved in the treatment of sexually transmitted infections and other urological indications. The company is dedicated to innovative therapeutic approaches and researching new drugs to improve the quality of life for patients and provide them with new treatment options. Veru Inc. has a strong foundation in medical research and development and collaborates with renowned experts in the fields of oncology and urology. Investing in Veru Inc. (VERU) shares may represent an attractive choice for investors who follow the pharmaceutical sector and seek a company with potential in innovative treatments for oncological and urological diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Mitchell S. Steiner
Employees
20
Headquarters
Miami
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number